A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors.
Zhichao Jiang, Wen Zhang, Chunxia Du et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I study assessed the pharmacokinetics and safety of nimotuzumab combined with irinotecan in Chinese patients with advanced solid tumors. A total of 67 patients participated, with results showing that the area under the concentration curve (AUC 0-∞) for nimotuzumab increased with dosage, reaching 446.3 ± 100.7 (600 mg) (×100 h µg/mL) for multiple doses. The combination demonstrated a manageable safety profile.
Key findings
- AUC 0-∞ for nimotuzumab increased with dosage: 446.3 ± 100.7 (600 mg) for multiple doses.
- Low incidence of rash was observed among patients.
- No dose-limiting toxicities occurred during the study.
Why it matters
Understanding the pharmacokinetics and safety of new drug combinations is crucial for optimizing treatment strategies in oncology. This study provides insights into the tolerability of nimotuzumab with irinotecan, which may inform future clinical applications.